Versant Ventures and Westlake BioPartners led a $50m Series A round in AllRock Bio.

Versant Ventures and Westlake BioPartners, a venture capital firms, led a $50m Series A round in AllRock Bio, a clinical-stage biotechnology company. "Today's launch highlights the value of our pan-ROCK inhibitor approach, which addresses the fundamental drivers, not just the symptoms, of cardiopulmonary diseases, beginning with PAH and ILD-PH. In identifying this asset, we listened to KOLs and clinicians who emphasized the importance of developing a therapy that blocks the non-redundant roles of both ROCK1 and ROCK2," Catherine Pearce, AllRock CEO and Co-Founder.